Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

CytomX is Rallying Today! The Firm Will Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

May 1, 2024 0

CytomX Therapeutics CytomX Therapeutics, Inc. (CTMX) announced that it will report first quarter 2024 results and …

TG Therapeutics Stock Price is Rising as Q1 Revenues from BRIUMVI U.S. Have Exceeded Expectations

May 1, 2024 0

TG Therapeutics Financial Results for Q1 2024 TG Therapeutics, Inc. (TGTX) announced its financial results for …

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

April 30, 2024 0

From Akero Therapeutics Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics remarked, …

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who Continued to Receive XPro Product

April 30, 2024 0

INmune Bio Press Release INmune Bio (NASDAQ: INMB) is pleased to share an update on two …

U.S. FDA Approved Pfizer’s BEQVEZ™ – A One-Time Gene Therapy for Adults with Hemophilia B

April 26, 2024 0

Pfizer Approval A one-time dose of the Pfizer product, BEQVEZ, has reduced bleeds post-treatment compared to …

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

April 25, 2024 0

Vertex Pharmaceuticals and TreeFrog Therapeutics in the NEWS Vertex Pharmaceuticals (VRTX) and TreeFrog Therapeutics announced that …

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

April 25, 2024 0

Regeneron Pharmaceuticals and Mammoth Biosciences in the NEWS Regeneron Pharmaceuticals (REGN) and Mammoth Biosciences, Inc. announced a …

The U.S. FDA Approved Immunity Bio’s ANKTIVA® for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

April 23, 2024 0

Immunity Bio in the NEWS Immunity Bio (IBRX) - an immunotherapy company, announced that the U.S. …

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3 Adjunctive Trial for Parkinson’s Disease

April 20, 2024 0

Cerevel Therapeutics in the NEWS Cerevel Therapeutics (CERE) announced positive topline results from its pivotal Phase …

Vertex Pharmaceuticals Announces Advancements of Its Product Suzetrigine for Acute and Neuropathic Pain

April 18, 2024 0

Vertex Pharmaceuticals in the NEWS Vertex Pharmaceuticals (VRTX) announced advancements across its suzetrigine pain program, which …

Voyager Therapeutics: Demonstrating Productivity in Collaboration with Neurocrine to Advance Gene Therapies for Neurological Diseases

April 17, 2024 0

Voyager Therapeutics Voyager Therapeutics (VYGR) is a biotech company dedicated to leveraging the power of human …

Answers About Vertex Pharmaceuticals Acquisition of Alpine Immune. See Also: Important News from Coya Therapeutics on ALS

April 11, 2024 0

Vertex Pharmaceuticals Acquisition of Alpine Immune Sciences We start this posting by answering a question by …

Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

April 9, 2024 0

Syndax Pharmaceuticals in the NEWS Yesterday, Syndax Pharmaceuticals (NASDAQ: SNDX) announced the presentation of positive data …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

CytomX is Rallying Today! The Firm Will Report Q1 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

TG Therapeutics Stock Price is Rising as Q1 Revenues from BRIUMVI U.S. Have Exceeded Expectations

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who Continued to Receive XPro Product

U.S. FDA Approved Pfizer’s BEQVEZ™ – A One-Time Gene Therapy for Adults with Hemophilia B

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

The U.S. FDA Approved Immunity Bio’s ANKTIVA® for the Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3 Adjunctive Trial for Parkinson’s Disease

Vertex Pharmaceuticals Announces Advancements of Its Product Suzetrigine for Acute and Neuropathic Pain

Voyager Therapeutics: Demonstrating Productivity in Collaboration with Neurocrine to Advance Gene Therapies for Neurological Diseases

Answers About Vertex Pharmaceuticals Acquisition of Alpine Immune. See Also: Important News from Coya Therapeutics on ALS

Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Madrigal Pharmaceuticals Announces U.S. Availability of its Newly Approved Product Rezdiffra

Johnson & Johnson to Acquire Shockwave Medical

BioStem Technologies’ Press Release and Conference Call Offered Encouraging News

BioStem Technologies is Releasing its Fourth Quarter 2023 Financial Results Now

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

AbbVie Inc’s Two Different, Yet, Positive Impacting News

Novo Nordisk Aims to Acquire Cardior Pharmaceuticals, Strengthening Its Pipeline in Cardiovascular Disease